Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2008-03-18
2008-03-18
Saunders, David A. (Department: 1644)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007400, C435S007930, C435S007950, C436S506000, C436S507000
Reexamination Certificate
active
07344846
ABSTRACT:
The invention relates to methods for diagnosing and treating macular degeneration-related disorders. The invention also related to methods for identifying genes that cause macular degeneration-related disorders.
REFERENCES:
patent: 3654090 (1972-04-01), Schuurs et al.
patent: 5405749 (1995-04-01), Polans et al.
patent: 5472939 (1995-12-01), Fearon et al.
patent: 5681571 (1997-10-01), Holmgren et al.
patent: 5686598 (1997-11-01), North et al.
patent: 5705380 (1998-01-01), North et al.
patent: 5773573 (1998-06-01), Holms
patent: 5843449 (1998-12-01), Boots et al.
patent: 5951984 (1999-09-01), Kaneko et al.
patent: 6087120 (2000-07-01), Van Oeveren et al.
patent: 6103235 (2000-08-01), Neville et al.
patent: 6153203 (2000-11-01), Holmgren et al.
patent: 7011952 (2006-03-01), Hageman et al.
patent: 2002/0015957 (2002-02-01), Hageman et al.
patent: 2002/0102581 (2002-08-01), Hageman et al.
patent: 2003/0207309 (2003-11-01), Hageman et al.
patent: WO 90/15152 (1990-12-01), None
patent: WO 95/17673 (1995-06-01), None
patent: WO 97/38004 (1997-10-01), None
patent: WO 00/52479 (2000-09-01), None
Chen, H. et al. “An immunologic study of age-related macular degeneration” Yan Ke Xue Bao, Sep. 1993, pp. 113-120, vol. 9, No. 3.
Gurne, D. et al; “Antiretinal Antibodies in Serum of Patients with Age-related Macular Degeneration”, Opthalmology; May 1991; pp. 602-607, vol. 98, No. 5.
Penfold, P. et al; “Autoantibodies to retinal astrocytes associated with age-related macular degeneration”, Graefe's Archive for Clinical and Experimental Ophthalmology, 1990, pp. 270-274, vol. 228.
Access. No. 87011665 MEDLINE, Doc. No. PubMed ID: 2428981, “An enzyme immunoassay for auto-antibodies to keratin in normal human serum and in pleural fluids from patients with various malignant or non-malignant lung diseases”, Lambre et al, Journal of clinical & laboratory immunology, (1986) vol. 20, No. 4, pp. 171-176.
Abraha, A. and Luzio, J.; “Inhibition of the formation of the complement membrane-attack complex by a monoclonal antibody to the complement component C8α Subunit”,Biochem J, 1989, pp. 933-936; 264, Great Britain.
Akiyama, H. et al; “Inflammation and Alzheimer's disease”;Neurobioy of Aging 21; May-Jun. 2000; pp. 383-421; vol. 21, No. 3.
Allikmets, R. et al; “Mutation of the Stargardt Disease Gene (ABCR) in Age-Related Macular Degeneration”,Science, Sep. 19, 1997; pp. 1805-1807, vol. 277.
Auda, G. et al; “Measurement of complement activation products in patients with chronic rheumatic diseases”,Rheumatology International; 1990, 10(5):pp. 185-189, Springer-Verlag.
Baatrup, G. et al; “Effects of coagulation temperature on measurements of complement function in serum samples from patients with systemic lupus erythematosus”,Annuals of Rheumatic Disease, 1992, 51(7):892-897.
Bachinsky, D. et al; “Detection of Two Forms of GP330”,American Journal of Pathology.; Aug. 1993, pp. 598-611, vol. 143, No. 2.
Bhakdi, S. & Tranum-Jensen, J.; “Membrane Damage by Complement”,Biochimica et Biophysica Acta; 1983, pp. 343-372; 737, Elsevier Science Publishers B.V.
Bora, N.S. et al.; “Differential expression of the complement regulatory proteins in the human eye”,Investigative Ophthalmology&Visual Science; Dec. 1993, pp. 3579-3584, vol. 34, No. 13.
Braley-Mullen; “Activation of Distinct Subsets of T Suppressors Cells with Type III Pheumococcal Polysaccharide Coupled to Syngeneic Spleen Cells”,Immunological Tolerance To Self and Non-Self, Annals of New York Academy of Science, 1982, pp. 156-166, vol. 392.
Burger, R. et al; “The C Terminus of the Anaphylatoxin C3a Generated Upon Complement Activation Represents a Neoantigenic Determinant with Diagnostic Potential”,Journal of Immunology, Jul. 15, 1988; pp. 553-558, vol. 141 No. 2, Printed in the U.S.A.
Buyon, J. et al.; “Assessment of Disease Activity and Impending Flare in Patients with Systemic Lupus Erythematosus”,Arthritis and Rheumatism; Sep. 1992, pp. 1028-1037, vol. 35, No. 9.
Campbell, R. et al; “An Anion Binding Study of Vanadyl(IV) Human Serotransferrin”,Journal of Biological Chemistry, 1977, pp. 5996-6001, vol. 252, No. 17, Printed in the U.S.A.
Caraher, E.M. et al; “Evidence for enhanced rates of complement activation in serum from patients with newly diagnosed insulin-dependent diabetes mellittus exposed to rat islet cells and complement-dependent induction of islet cell apoptosis.”,Journal of Endocrinology; 1999, pp. 143-153, vol. 162, No. 1, Printed in Great Britain.
Chenoweth, D. et al; “Complement Activation During Cardiopulmonary Bypass”,New England Journal of Medicine; Feb. 26, 1981; pp. 497-502, vol. 304, No. 9, Printed in the U.S.A.
Chain, B. et al; “Improvement of the vitro T cell proliferation assay by a modified method that separates the antigen recognition and IL-2-dependent steps.”,Journal of Immunological Methods; 1987, pp. 221-228, vol. 99.
Debrock, S. and Declerck, P.; “Characterization of common neoantigenic epitopes generated in plasminogen activator inhibitor-1 after cleavage of the reactive center loop or after complex formation with various serin proteinases.”,FEBS Letters; 1995, pp. 243-246, vol. 376.
Delori, F. and Ben-Sira, I.; “Excitation and emission spectra of fluorescein dye in the human ocular fundus.”,Investigative Ophthalmology; Jun. 1975, pp. 487-492, vol. 14, No. 6.
Delori, F. et al; “In Vivo Fluorescence of the Ocular Fundus Exhibits Retinal Pigment Epithelium Lipofuscin Characteristics”,Investigative Ophthalmology&Visual Science; Mar. 1995, pp. 718-729, vol. 36, No. 3.
Detrick, B. et al.; “Class II Antigen Expression and Gamma Interferon Modulation of Monocytes and Retinal Pigment Epithelial Cells from Patients with Retinitis Pigmentosa”,Clinical Immunology and Immunopathology, Aug. 1985, pp. 201-211, vol. 36, No. 2, San Diego, CA, U.S.A.
Edwards, A. et al; “Malattia Leventinese: Refinement of the Genetic Locus and Phenotyic Variability in Autosomal Dominant Macular Drusen”,American Journal of Ophthalmology; Sep. 1998, pp. 417-424, vol. 126, Elsevier Science Inc.
Egerton, M. et al; “Identification of Ezin as an 81-kDa Tyrosin-Phosphorylated Protein in T Cells”,The Journal of Immunology, Sep. 15, 1992; pp. 1847-1852, vol. 149, No. 6, Printed in the U.S.A.
Enk, C. et al; “A Standardized Human T-lymphocyte Proliferation Assay for Detecting Soluble Accessory Factors From Monocytes”, Acta Pathol Microbiol Immunol Scand [C], 1984, pp. 93-100, vol. 92, No. 2.
Epstein, G.A. and Rabb, M.F.; “Adult vitelliform macular degeneration: diagnosis and natural history”;British Journal of Ophthalmology; 1980, pp. 733-740, vol. 64.
Felbor, U. et al; “Adult vitelliform Macular Dystrophy is Frequently Associated With Mutations in the Peripherin/RDS Gene”,Human Mutation; 1997, pp. 301-309, vol. 10.
Felbor, U. et al; “Autosomal Recessive Sorsby Fundus Dystrophy Revisited: Molecular Evidence for Dominant Inheritance”,American Journal of Human Genetics; 1997, pp. 57-62, vol. 60.
Fitzgibbon, J. et al; “Localisation of the human blue cone pigment gene to chromosome band 7q31.3-32”,Human Genetics; 1994, pp. 79-80, vol. 93.
Forstrom, J.W. et al; Immunization to a syngeneic sarcoma by a monoclonal auto-anti-idiotypic antibody,Nature; Jun. 16, 1983; pp. 627-629, vol. 303.
Giltay, R. et al; “Sequence, Recombinant Expression and Tissue Localization of Two Novel Extracellular Matrix Proteins,fibulin-3andfibulin-4”, Matrix Biol, Oct. 1999, pp. 469-480, vol. 18, No. 5.
Gorski, J; “Quantitation of Human Complement Fragment C4ai in Physiological Fluids by Competitive Inhibition Radioimmune Assay”,Journal of Immunological Methods; 1981, pp. 61-73, vol. 47, Elsevier/North-Holland Biomedical Press.
Goslings
Hageman Gregory S.
Mullins Robert F.
Saunders David A.
Townsend and Townsend / and Crew LLP
University of Iowa Research Foundation
LandOfFree
Diagnostics and therapeutics for macular... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diagnostics and therapeutics for macular..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diagnostics and therapeutics for macular... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2800518